Thermo Fisher Scientific's board this week established base salaries, bonuses, and other forms of compensation for the company's executives and approved the payout of 2009 bonuses for its executives under the company's 2008 Annual Incentive Award Plan.
According to a document filed with the US Securities and Exchange Commission, under the plan set out by the board, President and CEO Marc Casper will receive a base salary of $1 million for 2010. His target bonus for 2010 is 115 percent of his base salary, or $1.15 million.
His cash bonus for 2009 is $824,533.
Senior Vice President and Chief Financial Officer Peter Wilver's base salary for 2010 will be $616,000 with a target bonus of 75 percent of his base salary, or $462,000. He is receiving a cash bonus of $450,000 for 2009.
Senior Vice President Alan Malus' base salary for 2010 is $570,000 and his target bonus will be 75 percent of his base salary, or $427,500. His cash bonus for 2009 is $459,824.
Senior Vice President, General Counsel, and Secretary Seth Hoogasian will have a base salary of $494,500 and a target bonus of 65 percent of his base salary, or $321,425. His cash bonus for 2009 is $312,975.
All base salaries become effective April 5.
Thermo Fisher also announced that Stephen Kaufman and Michael Bell have told the firm they will not stand for re-election to the company's board. Their terms will expire at the company's 2010 annual meeting of stockholders.
Diagnostics For All this week announced Una Ryan is its president and CEO, replacing James Barber.
Ryan has more than 20 years of executive experience in biotechnology and pharmaceuticals, DFA said in a statement. Most recently, she was CEO of Waltham Technologies. Before that she was president and CEO of Avant Immunotherapeutics.
DFA has exclusive rights to paper-based microfluidic lab-on-a-chip technology developed by George Whitesides, its co-founder and a professor of chemistry at Harvard University. The chip detects proteins for the diagnosis of disease [See related story this issue.]
Barber had served as CEO of DFA on a part-time, unpaid basis since the company's founding, a DFA spokesman said. The company began a search for a full-time CEO as the "organization grew to the point it needed a full-time leader who could bring the technology to its intended users," he added.
Harald Mischak has been appointed chair of proteomics at the University of Glasgow, the school announced earlier this month.
His appointment took effect Feb. 5. He will lead proteomics research within the British Heart Foundation Glasgow Cardiovascular Research Center at the university.
Mischak is the founder of German biomarker firm Mosaiques Diagnostics and Therapeutics, where he is a director. He was formerly a professor in the department of nephrology at the Medical School of Hannover.